We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

52 hedge funds and large institutions have $137M invested in PDS Biotechnology in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

0.07% more ownership

Funds ownership: 2.52% → 2.58% (+0.07%)

0% more funds holding

Funds holding: 52 → 52 (0)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

25% less capital invested

Capital invested by funds: $182M → $137M (-$45.4M)

Holders
52
Holders Change
–
Holders Change %
0%
% of All Funds
1.29%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
9
Increased
19
Reduced
15
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.26M
2
ACP
Acuta Capital Partners
California
+$3.08M
3
RC
RegentAtlantic Capital
New Jersey
+$1.34M
4
Franklin Resources
Franklin Resources
California
+$1.09M
5
Millennium Management
Millennium Management
New York
+$754K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.56M
2
JHIU
Janus Henderson Investors US
Colorado
-$475K
3
Goldman Sachs
Goldman Sachs
New York
-$361K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$328K
5
Morgan Stanley
Morgan Stanley
New York
-$261K
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$256K +$98.6K +498 +55%
TC
27
TFS Capital
Pennsylvania
$209K +$228K +1,150 New
Morgan Stanley
28
Morgan Stanley
New York
$199K -$261K -1,317 -55%
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$158K – – –
SIM
30
Spark Investment Management
New York
$157K +$171K +863 New
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$153K +$7.53K +38 +5%
TI
32
Trexquant Investment
Connecticut
$143K +$155K +783 New
MSFP
33
Mark Sheptoff Financial Planning
Connecticut
$140K -$4.95K -25 -3%
Manulife (Manufacturers Life Insurance)
34
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$131K +$16.2K +82 +13%
Wells Fargo
35
Wells Fargo
California
$109K +$1.98K +10 +2%
Russell Investments Group
36
Russell Investments Group
United Kingdom
$93K +$101K +511 New
AIG
37
American International Group
New York
$91K +$6.73K +34 +7%
NFA
38
Nationwide Fund Advisors
Ohio
$84K -$9.71K -49 -10%
Legal & General Group
39
Legal & General Group
United Kingdom
$37K -$792 -4 -2%
Deutsche Bank
40
Deutsche Bank
Germany
$35K -$56.4K -285 -59%
Bank of America
41
Bank of America
North Carolina
$31K +$8.12K +41 +32%
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$28K -$3.56K -18 -11%
PCC
43
Park Circle Company
Maryland
$11K – – –
KTC
44
Kistler-Tiffany Companies
Pennsylvania
$10K – – –
SO
45
STRS Ohio
Ohio
$9K – – –
AIM
46
Advantage Investment Management
Iowa
$8K +$3.96K +20 +80%
AIP
47
Ameritas Investment Partners
Nebraska
$8K +$8.91K +45 New
UBS Group
48
UBS Group
Switzerland
$4K -$37.2K -188 -89%
MAM
49
Meeder Asset Management
Ohio
$2K +$2.58K +13 New
Citigroup
50
Citigroup
New York
$1K -$161K -814 -100%
1
2
3

PDSB Hedge Fund Activity: Q1 2017 in Review

52 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2017, worth a combined $137M — down 25% from $182M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PDSB positions and 4 closed out — a net gain of 5 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $7.26M. The largest seller was Fidelity Investments, cutting an estimated $1.56M.

  • 52 institutional investors held PDS Biotechnology (PDSB) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $137M of PDS Biotechnology stock for Q1 2017, down 25% quarter-over-quarter.
  • 9 funds opened new PDS Biotechnology positions in Q1 2017 and 4 closed out, a net change of +5 holders.
  • The largest PDS Biotechnology buyer in Q1 2017 was BlackRock, an estimated $7.26M added.
  • The largest PDS Biotechnology seller in Q1 2017 was Fidelity Investments, an estimated $1.56M sold.

Based on aggregated 13F filings for Q1 2017.